Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

Current Oncology

Volumn 15, Issue 6, 2008, Pages 25-31

  Melosky, Barbara ^a   Agulnik, J ^b   Assi, H ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONCTON HOSPITAL   (Canada)

Author keywords

EGFR; Epidermal growth factor receptor; Erlotinib; Non small cell lung cancer; NSCLC; Retrospective practice review; Second line; TKI; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; AGED; ASIAN; CANADA; CANCER GROWTH; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; PHYSICAL PERFORMANCE; RASH; RECURRENT CANCER; REVIEW; SEX DIFFERENCE; SMOKING; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 68749100871     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2008. Toronto: Canadian Cancer Society; 2008.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4-66.
3. International Agency for Research on Cancer (IARC). GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide [electronic tool]. Lyon, France: IARC; 2005. [AvaWlable online from: www-dep.iarc.fr/globocan/downloads.htm; cited November 5, 2008]
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
5. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62.
6. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
7. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. on behalf of the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
9. Stinchcombe TE, Socinski MA. Considerations for secondline therapy of non-small cell lung cancer. Oncologist 2008;13(suppl 1):28-36.
10. Ramalingam S, Sandler AB. Salvage therapy for advanced nonsmall cell lung cancer: Factors influencing treatment selection. Oncologist 2006;11:655-65.
11. Hoffmann-La Roche Ltd. Tarceva (erlotinib) product monograph. Rev ed. Mississauga, ON: Hoffmann-La Roche; April 1, 2008.
12. Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005;11:795-802.
13. Cascone T, Morelli MP, Ciardiello F. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in nonsmall cell lung cancer. Ann Oncol 2006;17(suppl 2):iI46-8.
14. Herbst RS, Bunn PA Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003;9:5813-24.
15. Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006;7:389-94.
16. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-54.
17. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-smallcell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004;22:777-84.
18. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004;22:785-94.
19. Herbst RS, Prager D, Hermann R, et al. on behalf of the TRIBUTE Investigator Group. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
20. Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: Case closed or is the jury still out? J Clin Oncol 2005;23:5856-8.
21. Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in nonsmall-cell lung cancer. Clin Lung Cancer 2006;7:385-8.
22. Douillard JY, Kim E, Hirsh V, et al. Getinib (Iressa) versus docetaxel in patients with locally advanced or metastatic nonsmall cell lung cancer pre-treated with platinum-based chemotherapy: A randomized, open-label phase III study (INTEREST) [abstract PRS-02]. J Thorac Oncol 2007;2(suppl 4):S305.
23. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: A phase II study. Clin Cancer Res 2006;12:6049-55.
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
26. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
27. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-21.
28. Ng R, Loreto M, Lee R, Leighl NB. Brief report: Retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer 2008;61:262-5.
29. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist 2007;12:610-21.
30. Gridelli C, Maione P, Amoroso D, et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting. Crit Rev Oncol Hematol 2008;66:155-62.